Bosutinib for CML After Progression With First-line TKI

Share this content:
Bosutinib has shown promise in patients with Philadelphia-positive chronic phase chronic myeloid leukemia.
Bosutinib has shown promise in patients with Philadelphia-positive chronic phase chronic myeloid leukemia.

Bosutinib, a dual Src/Abl tyrosine kinase inhibitor (TKI), has shown promise in patients with Philadelphia-positive (Ph+) chronic phase chronic myeloid leukemia (CML-CP) who have progressed on conventional TKIs such as imatinib and dasatinib, according to a study published in the American Journal of Hematology.1

Patients who have been treated with first- or second-generation TKIs may experience increased recurrence or may not tolerate the adverse effects associated with these medications, such as fluid retention or bleeding disorders. The objective of this study was to analyze the efficacy and safety of bosutinib among patients with CML who progressed on first-line TKI therapy.

In this ongoing, prospective, phase 1/2 trial, researchers evaluated 119 patients who had Ph+ diagnosis, and who had received first and second generation TKIs. Efficacy endpoints included complete hematologic response (CHR), complete cytogenetic response (CCyR), and major cytogenetic response (MCyR). If present, these measures were analyzed at baseline.

Patients on bosutinib had a confirmed CHR rate of 74% (95% CI, 65-81%); for patients who had CHR at baseline, 87% had at least a 4-week maintenance period. Among patients who acquired a new or maintained a MCyR for 4 weeks, the cumulative MCyR rate was 40% (95% CI, 31-50%).

RELATED: CD62L Plasma Levels May Predict Response to TKIs in Early CML-CP

The researchers conclude that bosutinib might be beneficial for patients who have progressed on imatinib or dasatinib/nilotinib as first-line options. The adverse effects of bosutinib were minimal and tolerable compared to other TKIs used for CML-CP.

Reference

  1. Cortes JE, Khoury HJ, Kantarjian HM, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016 Sep 15. doi: 10.1002/ajh.24536 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs